denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Global Blood Therapeutics
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
sickle cell disease, Biological, Diseases, bone marrow, Non-Biological, Therapies, red blood cells, Hemoglobinopathies, gene therapy, Technology and Procedures, Cell Lineage, gene editing, Clinically relevant, transfusion, pharmacology, Quality Improvement
Hematology Disease Topics & Pathways:
sickle cell disease, Biological, Diseases, bone marrow, Non-Biological, Therapies, red blood cells, Hemoglobinopathies, gene therapy, Technology and Procedures, Cell Lineage, gene editing, Clinically relevant, transfusion, pharmacology, Quality Improvement
Friday, December 4, 2020: 7:00 AM-10:00 AM
Chair:
Jane S. Hankins, MD, MS, St. Jude Children's Research Hospital
Disclosures:
Hankins: National Heart, Lung, and Blood Institute: Honoraria, Research Funding; Global Blood Therapeutics: Consultancy, Research Funding; LINKS Incorporate Foundation: Research Funding; UptoDate: Consultancy; Novartis: Research Funding; American Society of Pediatric Hematology/Oncology: Honoraria; MJH Life Sciences: Consultancy, Patents & Royalties.
Speakers:
Daniel E. Bauer, MD, PhD, Boston Children’s Hospital
,
Modupe Idowu, MD, University of Texas Health Science Center, McGovern Medical School
,
Caterina P. Minniti, MD, Albert Einstein College of Medicine
and
Akshay Sharma, MBBS, St. Jude Children's Research Hospital
Disclosures:
Bauer: Pfizer: Consultancy; Syros Pharmaceuticals: Consultancy. Idowu: Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Research Funding; Cyclerion Therapeutics, Inc: Research Funding. Minniti: Emmaus: Consultancy; CLS Behring: Consultancy; Forma: Consultancy; Global Blood Therapeutics: Membership on an entity's Board of Directors or advisory committees; Teutona: Membership on an entity's Board of Directors or advisory committees; Bluebird Bio: Other; Sodium Nitrate for SCD leg ulcers: Patents & Royalties; Roche: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees. Sharma: Vertex Pharmaceuticals: Research Funding; CRISPR Therapeutics: Research Funding; Novartis: Research Funding; Spotlight Therapeutics: Consultancy.
This continuing medical education symposium will address continuing and emerging educational needs in the care and management of patients with sickle cell disease (SCD). Experts in the field will provide didactic presentations and panel discussions to address persisting challenges in the management of SCD, the burden of disease, and provide guidance to integrate current and emerging management strategies into the clinic to enhance patient care and quality of life measures. Patient perspective videos will be utilized to further highlight the burden of SCD on mental health, quality of life, and its psychosocial impact. Current and emerging therapeutic options with the potential to limit disease burden and enhance quality of life will be evaluated for safety and efficacy to provide insight for their optimal integration into individualized treatment algorithms.
See more of: Satellite Symposia